當前位置：首頁 JCRQ1 期刊介紹(非官網)

Drug Design Development And TherapySCIE

國際簡稱：DRUG DES DEV THER 參考譯名：藥物設計開發和治療

中科院分區
2區
CiteScore分區
Q1
JCR分區
Q1

基本信息：: ISSN：1177-8881; 是否OA：開放; 是否預警：否; TOP期刊：是

出版信息：: 出版地區：ENGLAND; 出版商：Dove Medical Press Ltd.; 出版語言：English; 出版周期：1 issue/year; 出版年份：2007; 研究方向：CHEMISTRY, MEDICINAL-PHARMACOLOGY & PHARMACY

評價信息：: 影響因子：4.7; H-index：48; CiteScore指數：9; SJR指數：0.999; SNIP指數：1.124

發文數據：: Gold OA文章占比：97.50%; 研究類文章占比：80.08%; 年發文量：256; 自引率：0; 開源占比：0.9689; 出版撤稿占比：0.0043...; 出版國人文章占比：0.52; OA被引用占比：1

投稿咨詢加急見刊

英文簡介期刊介紹 CiteScore數據中科院SCI分區 JCR分區發文數據常見問題

英文簡介Drug Design Development And Therapy期刊介紹

Drug Design, Development and Therapy is an international, peer-reviewed, open access journal that spans the spectrum of drug design, discovery and development through to clinical applications.

The journal is characterized by the rapid reporting of high-quality original research, reviews, expert opinions, commentary and clinical studies in all therapeutic areas.

Specific topics covered by the journal include:

Drug target identification and validation

Phenotypic screening and target deconvolution

Biochemical analyses of drug targets and their pathways

New methods or relevant applications in molecular/drug design and computer-aided drug discovery*

Design, synthesis, and biological evaluation of novel biologically active compounds (including diagnostics or chemical probes)

Structural or molecular biological studies elucidating molecular recognition processes

Fragment-based drug discovery

Pharmaceutical/red biotechnology

Isolation, structural characterization, (bio)synthesis, bioengineering and pharmacological evaluation of natural products**

Distribution, pharmacokinetics and metabolic transformations of drugs or biologically active compounds in drug development

Drug delivery and formulation (design and characterization of dosage forms, release mechanisms and in vivo testing)

Preclinical development studies

Translational animal models

Mechanisms of action and signalling pathways

Toxicology

Gene therapy, cell therapy and immunotherapy

Personalized medicine and pharmacogenomics

Clinical drug evaluation

Patient safety and sustained use of medicines.

期刊簡介Drug Design Development And Therapy期刊介紹

《Drug Design Development And Therapy》自2007出版以來，是一本醫學優秀雜志。致力于發表原創科學研究結果，并為醫學各個領域的原創研究提供一個展示平臺，以促進醫學領域的的進步。該刊鼓勵先進的、清晰的闡述，從廣泛的視角提供當前感興趣的研究主題的新見解，或審查多年來某個重要領域的所有重要發展。該期刊特色在于及時報道醫學領域的最新進展和新發現新突破等。該刊近一年未被列入預警期刊名單，目前已被權威數據庫SCIE收錄，得到了廣泛的認可。

該期刊投稿重要關注點：

預計審稿時間： 12周，或約稿
國際TOP期刊
醫學
CHEMISTRY, MEDICINAL
SCIE
中科院2區
非預警

Cite Score數據（2024年最新版）Drug Design Development And Therapy Cite Score數據

CiteScore：9
SJR：0.999
SNIP：1.124

學科類別	分區	排名	百分位
大類：Pharmacology, Toxicology and Pharmaceutics 小類：Pharmaceutical Science	Q1	24 / 183	87%
大類：Pharmacology, Toxicology and Pharmaceutics 小類：Pharmacology	Q1	48 / 313	84%
大類：Pharmacology, Toxicology and Pharmaceutics 小類：Drug Discovery	Q1	27 / 157	83%

CiteScore 是由Elsevier(愛思唯爾)推出的另一種評價期刊影響力的文獻計量指標。反映出一家期刊近期發表論文的年篇均引用次數。CiteScore以Scopus數據庫中收集的引文為基礎，針對的是前四年發表的論文的引文。CiteScore的意義在于，它可以為學術界提供一種新的、更全面、更客觀地評價期刊影響力的方法，而不僅僅是通過影響因子(IF)這一單一指標來評價。

歷年Cite Score趨勢圖

中科院SCI分區Drug Design Development And Therapy 中科院分區

中科院 2023年12月升級版 綜述期刊：否 Top期刊：否

大類學科	分區	小類學科	分區
醫學	2區	CHEMISTRY, MEDICINAL 藥物化學 PHARMACOLOGY & PHARMACY 藥學	2區 2區

中科院分區表 是以客觀數據為基礎，運用科學計量學方法對國際、國內學術期刊依據影響力進行等級劃分的期刊評價標準。它為我國科研、教育機構的管理人員、科研工作者提供了一份評價國際學術期刊影響力的參考數據，得到了全國各地高校、科研機構的廣泛認可。

中科院分區表 將所有期刊按照一定指標劃分為1區、2區、3區、4區四個層次，類似于“優、良、及格”等。最開始，這個分區只是為了方便圖書管理及圖書情報領域的研究和期刊評估。之后中科院分區逐步發展成為了一種評價學術期刊質量的重要工具。

歷年中科院分區趨勢圖

JCR分區Drug Design Development And Therapy JCR分區

2023-2024 年最新版

按JIF指標學科分區	收錄子集	分區	排名	百分位
學科：CHEMISTRY, MEDICINAL	SCIE	Q1	17 / 72	77.1%
學科：PHARMACOLOGY & PHARMACY	SCIE	Q1	55 / 354	84.6%

按JCI指標學科分區	收錄子集	分區	排名	百分位
學科：CHEMISTRY, MEDICINAL	SCIE	Q1	17 / 72	77.08%
學科：PHARMACOLOGY & PHARMACY	SCIE	Q1	68 / 354	80.93%

JCR分區的優勢在于它可以幫助讀者對學術文獻質量進行評估。不同學科的文章引用量可能存在較大的差異，此時單獨依靠影響因子(IF)評價期刊的質量可能是存在一定問題的。因此，JCR將期刊按照學科門類和影響因子分為不同的分區，這樣讀者可以根據自己的研究領域和需求選擇合適的期刊。

歷年影響因子趨勢圖

發文數據

2023-2024 年國家/地區發文量統計

國家/地區數量
CHINA MAINLAND770
USA91
South Korea61
Egypt55
Saudi Arabia53
Italy39
Iran30
GERMANY (FED REP GER)27
Malaysia25
Pakistan25

本刊中國學者近年發表論文

1、Binary Nanodrug-Delivery System Designed for Leukemia Therapy: Aptamer- and Transferrin-Codecorated Daunorubicin- and Luteolin-Coloaded Nanoparticles
Author: Zhu, Yuanyuan; Zhang, Wei; Chen, Jing

Journal: DRUG DESIGN DEVELOPMENT AND THERAPY. 2023; Vol. 17, Issue , pp. 1-13. DOI: 10.2147/DDDT.S387246
2、Menthone Exerts its Antimicrobial Activity Against Methicillin Resistant Staphylococcus aureus by Affecting Cell Membrane Properties and Lipid Profile
Author: Zhao, Wenming; Yang, Chengwei; Zhang, Ning; Peng, Yuanyuan; Ma, Ying; Gu, Keru; Liu, Xia; Liu, Xiaohui; Liu, Xijian; Liu, Yumin; Li, Songkai; Zhao, Linjing

Journal: DRUG DESIGN DEVELOPMENT AND THERAPY. 2023; Vol. 17, Issue , pp. 219-236. DOI: 10.2147/DDDT.S384716
3、Evaluation of Chitosan-Oleuropein Nanoparticles on the Durability of Dentin Bonding
Author: Zhao, Shuya; Zhang, Yunyang; Chen, Yun; Xing, Xianghui; Wang, Yu; Wu, Guofeng

Journal: DRUG DESIGN DEVELOPMENT AND THERAPY. 2023; Vol. 17, Issue , pp. 167-180. DOI: 10.2147/DDDT.S390039
4、Efficacy and Mechanism of Qianshan Huoxue Gao in Acute Coronary Syndrome via Regulation of Intestinal Flora and Metabolites
Author: Zhao, Ning; Ma, Yan; Liang, Xiaoxue; Zhang, Yu; Hong, Dacheng; Wang, Ying; Bai, Dong

Journal: DRUG DESIGN DEVELOPMENT AND THERAPY. 2023; Vol. 17, Issue , pp. 579-595. DOI: 10.2147/DDDT.S396649
5、Network Pharmacology and Experimental Validation to Explore the Effect and Mechanism of Kanglaite Injection Against Triple-Negative Breast Cancer
Author: Zhao, Mei; Fu, Lijuan; Xu, Panling; Wang, Ting; Li, Ping

Journal: DRUG DESIGN DEVELOPMENT AND THERAPY. 2023; Vol. 17, Issue , pp. 901-917. DOI: 10.2147/DDDT.S397969
6、Network Pharmacology and Experimental Validation to Explore That Celastrol Targeting PTEN is the Potential Mechanism of Tripterygium wilfordii (L?v.) Hutch Against IgA Nephropathy
Author: Zhao, Juanyong; Liu, Haiyang; Xia, Ming; Chen, Qian; Wan, Lili; Leng, Bin; Tang, Chengyuan; Chen, Guochun; Liu, Yu; Zhang, Lei; Liu, Hong

Journal: DRUG DESIGN DEVELOPMENT AND THERAPY. 2023; Vol. 17, Issue , pp. 887-900. DOI: 10.2147/DDDT.S402503
7、Shensong Yangxin Capsule Reduces the Susceptibility of Arrhythmia in db/db Mice via Inhibiting the Inflammatory Response Induced by Endothelium Dysfunction
Author: Zhang, Jiehan; Li, Hongrong; Wang, Dandong; Gu, Jiaojiao; Hou, Yunlong; Wu, Yiling

Journal: DRUG DESIGN DEVELOPMENT AND THERAPY. 2023; Vol. 17, Issue , pp. 313-330. DOI: 10.2147/DDDT.S392328
8、Review on the Diverse Biological Effects of Glabridin
Author: Zhang, Jianhong; Wu, Xinhui; Zhong, Baiyin; Liao, Qicheng; Wang, Xin; Xie, Yuankang; He, Xiao

Journal: DRUG DESIGN DEVELOPMENT AND THERAPY. 2023; Vol. 17, Issue , pp. 15-37. DOI: 10.2147/DDDT.S385981